Literature DB >> 19609771

[Helicobacter pylori].

W Fischbach1.   

Abstract

Helicobacter pylori is associated with various gastroduodenal diseases such as peptic ulcer, functional dyspepsia, MALT lymphoma and distal gastric cancer. Diagnosis of H. pylori can be established by non-invasive ((13C)urea breath test, stool antigen test, serology) and invasive (histology, rapid urease test, culture) tests. In adults, culture and susceptibility testing should or must be performed after failing of first-line therapy in case of a control endoscopy and before third-line therapy, respectively. Peptic ulcer and gastric MALT lymphoma represent obligatory indications for eradication therapy. Other potential indications are functional dyspepsia, prevention of gastric cancer in individuals being at risk, and before starting treatment with traditional non-steroid antiphlogistics. First-line therapy is performed with a 7-days combination of proton pump inhibitor with clarithromycin and amoxicillin or metronidazole. In second-line therapy levofloxacin and rifabutin are good rescue antibiotics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609771     DOI: 10.1007/s00108-009-2438-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  11 in total

Review 1.  Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

Authors:  J P Gisbert; F Morena
Journal:  Aliment Pharmacol Ther       Date:  2006-01-01       Impact factor: 8.171

Review 2.  Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients.

Authors:  A C Ford; B C Delaney; D Forman; P Moayyedi
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

3.  [S3-guideline "Helicobacter pylori and gastroduodenal ulcer disease"].

Authors:  W Fischbach; P Malfertheiner; J C Hoffmann; W Bolten; J Bornschein; O Götze; W Höhne; M Kist; S Koletzko; J Labenz; P Layer; St Miehlke; A Morgner; U Peitz; J C Preiss; C Prinz; U Rosien; W E Schmidt; A Schwarzer; S Suerbaum; A Timmer; G Treiber; M Vieth
Journal:  Z Gastroenterol       Date:  2009-01-20       Impact factor: 2.000

4.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

5.  Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

Authors:  B J Marshall; J R Warren
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

6.  A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer.

Authors:  A Leodolter; M Kulig; H Brasch; W Meyer-Sabellek; S N Willich; P Malfertheiner
Journal:  Aliment Pharmacol Ther       Date:  2001-12       Impact factor: 8.171

7.  Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series.

Authors:  W Fischbach; M-E Goebeler-Kolve; B Dragosics; A Greiner; M Stolte
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

8.  One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.

Authors:  Stephan Miehlke; Wulf Schneider-Brachert; Christian Kirsch; Andrea Morgner; Ahmed Madisch; Eberhard Kuhlisch; Christian Haferland; Elke Bästlein; Claus Jebens; Christian Zekorn; Holger Knoth; Manfred Stolte; Norbert Lehn
Journal:  Helicobacter       Date:  2008-02       Impact factor: 5.753

9.  Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia.

Authors:  P Malfertheiner; J MOssner; W Fischbach; P Layer; A Leodolter; M Stolte; K Demleitner; W Fuchs
Journal:  Aliment Pharmacol Ther       Date:  2003-09-15       Impact factor: 8.171

Review 10.  The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis.

Authors:  Angelo Zullo; Vincenzo De Francesco; Cesare Hassan; Sergio Morini; Dino Vaira
Journal:  Gut       Date:  2007-06-12       Impact factor: 23.059

View more
  1 in total

Review 1.  Ureases: Historical aspects, catalytic, and non-catalytic properties - A review.

Authors:  Karine Kappaun; Angela Regina Piovesan; Celia Regina Carlini; Rodrigo Ligabue-Braun
Journal:  J Adv Res       Date:  2018-05-28       Impact factor: 10.479

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.